Skip to main content

Table 5 The number of potential drugs filtered by meta-analysis for early- and late- stage NSCLC using the enrichment score (ES) and cMap p-value (less than 0.1) for meta-analysis

From: Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory

  Early-stage Late-stage
Potential drugs IC50 verified Potential drugs IC50 verified
ES < 0 & cMap p-value <0.1 9 4 31 5
ES < 0 & cMap p-value <0.5 12 4 81 8
ES < 0 & p MA -value <0.05 25 2 23 1
ES < 0 & p MA -value <0.1 60 8 49 5